Startups
GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.
The strategic collaboration centers on Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing.
On Wednesday, Third Harmonic Bio closed on Series B financing, bringing the total capital raised to $155 million.
Star Therapeutics has exited stealth mode and announced a spin-off company, Electra Therapeutics.
TenSixteen Bio recently came out of stealth mode with $40 million in funding to target somatic mosaicism – particularly clonal hematopoiesis of indeterminate potential (CHIP).
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.
Roivant Sciences launches new subsidiary Hemavant that will develop Eisai-licensed asset for transfusion-dependent anemia in patients with low-risk MDS.
Curevo, a clinical-stage biotechnology company, is developing safe and highly-effective vaccines to fight infectious diseases such as shingles.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Seismic Therapeutic, Inc. announced its launch and financing of $101 million to fund two new programs and further develop its existing IMPACT™ platform.
PRESS RELEASES